Kiniksa heads into its third-quarter report with an unusual problem for a biotech: its own guidance may be more aggressive than the Street. After raising its 2026 revenue outlook for the second straight quarter, management now expects $980 million to $995 million in sales. Analysts' full-year consensus of roughly $939 million still sits below the bottom of that range. The question on October 27 is whether the quarter shows the recurrent pericarditis franchise accelerating fast enough to make the new range look comfortable rather than ambitious.
The arithmetic frames the setup. First-half revenue came to about $458 million, so hitting guidance requires roughly $522 million to $537 million in the back half, or an average of about $261 million to $269 million a quarter. Consensus for the September quarter is $259.5 million, up 43.5% from a year ago but only about $16 million above the second quarter's $243.6 million. That would be a sharp slowdown from the roughly $29 million sequential jump management called the largest since launch. It also ignores a timing wrinkle. Management flagged that gross-to-net deductions typically rise in the fourth quarter, and they ran at 7.2% year to date through June after 8.6% in the first quarter. That puts more of the burden on the third quarter, so a result near consensus could actually read as soft against the company's own trajectory. Earnings are expected at $0.39 a share, up nearly 70% from $0.23 a year earlier and up from $0.30 last quarter, which reflects profit growth outpacing sales.
The underlying demand metrics will matter as much as the headline number. Penetration among patients with multiple recurrences has climbed steadily, from about 13% at the end of 2024 to roughly 21% in the second quarter. The prescriber base topped 5,000 after about 450 new additions in the quarter. Continued gains on both measures would confirm that growth is broadening rather than relying on deeper use by existing doctors. This is also the first full quarter to measure the direct-to-consumer campaign launched in April. Management described early engagement as encouraging, and investors should want to see that translate into new patient starts. Collaboration profit rose 68% last quarter to $176.1 million, a touch slower than the 73% pace in the first quarter. Watch whether that rate holds as cost of goods, Phase 3 spending and marketing all climb. Cash rose to $525.9 million, and another quarterly build would underline that the company funds its pipeline from operations.
On the pipeline, KPL387 moved into its pivotal Phase 3 PASTORAL trial ahead of the year-end target after Phase 2 data supported a 300mg monthly dose. Commentary on enrollment pace would help validate that early start. The Phase 2 disclosure was an interim analysis, however, so durability and recurrence data remain outstanding. A competitor's inflammasome inhibitor readout in recurrent pericarditis also looms as an external risk. KPL1161, aimed at quarterly dosing, is slated to enter Phase 1 by year-end.
The market has already priced in a good deal of this confidence. Shares have gained 13.8% since the last report, about 9 points better than the S&P 500. At $79.70 they sit well above the 200-day moving average near $58.54. The entire post-earnings range of $67.35 to $84.06 lies above the prior quarter's $45 to $67.50 band, though the stock remains about 5% below its recent high. Sentiment has improved meaningfully, rising to 31.7% bullish from 18.5% ahead of the last report.
The central issue is sequential momentum. If revenue lands meaningfully above $260 million with penetration and prescribers still climbing, the raised outlook looks conservative and another lift becomes plausible. A print near consensus would leave the fourth quarter with too much to do against seasonal pricing headwinds, and that would test the story of steady acceleration that has carried the stock.